When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

Journal of Clinical Oncology

Volumn 19, Issue 8, 2001, Pages 2334-2356

  Yamauchi, H ^a   Stearns, V ^a   Hayes, D F ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PREDNISONE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL TRIAL; DIAGNOSTIC VALUE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0035871525     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.8.2334     Document Type: Review

References (138)

1. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer
2. Amplification of a novel v-erbB-2 related gene in human mammary carcinoma
3. The erbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands
4. The erbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors
5. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
6. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
7. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
8. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: Report of the American Society of Clinical Oncology Expert Panel
9. A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers
10. Prognostic factors and treatment decisions in axillary-node-negative breast cancer
11. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients
12. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?
13. New prognostic factors for breast cancer recurrence
14. Do we need prognostic factors in nodal-negative breast cancer? Arbiter
15. Experts debate value of HER2 testing methods
16. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
17. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease
18. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
19. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy
20. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients
21. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
22. Final report: Weekly herceptin and taxol for metastatic breast cancer: Analysis of efficacy by HER2 immunophenotype and gene amplification
23. Comparison of Fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
24. c-erbB-2 as a prognostic factor in breast cancer: A meta-analysis
25. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
26. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo
27. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
28. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells
29. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines
30. Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro
31. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer
32. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model
33. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
34. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185
35. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines
36. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
37. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
38. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
39. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial
40. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
41. First-line, nonhormonal treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab, humanized anti-HER2 antibody)
42. Enhanced antiproliferative activity of the combination of tamoxifen plus HER-2-neu antibody
43. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
44. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
45. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
46. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
47. 20 years update of the Naples GUN Trial of adjuvant breast cancer therapy: Evidence of interaction between c-erbB-2 expression and tamoxifen efficacy
48. HER2 overexpression predicts adjuvant tamoxifen failure for early breast cancer: Complete data at 20 years of the Naples GUN randomized trial
49. Lack of interaction of tamoxifen use and erbB-2/HER-2/neu expression in CALGB 8541: A randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin, and fluorouracil (CAF) in node-positive primary breast cancer
50. HER-2 and p53 expression vs. tamoxifen resistance in estrogen-receptor-positive node-positive breast cancer
51. Dose and dose intensity trial of adjuvant chemotherapy for Stage II, node positive breast carcinoma: Initial results of CALGB 8541
52. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
53. Results of prolonged adjuvant tamoxifen therapy of breast cancer correlated to steroid receptor, S-phase and erbB2 levels
54. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
55. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
56. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
57. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer
58. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
59. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
60. Cell biological factors associated with the response of breast cancer to systemic treatment
61. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer
62. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy
63. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity
64. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer
65. Prognostic significance of serum c-erbB-2 protein in breast cancer patients
66. Droloxifene, a new antiestrogen: Its role in metastatic breast cancer
67. Elevated circulating HER-2/neu related protein (NRP) is associated with poor survival in patients with metastatic breast cancer
68. Prognostic significance of c-erb-B2 amplification in fine-needle biopsies of breast cancer patients not operated at diagnosis
69. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms
70. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
71. Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells
72. Basic science of HER-2/neu: A review
73. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
74. Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20
75. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: Relationship to m-AMSA and mitoxantrone sensitivity
76. DNA topoisomerase-targeting antitumor agents and drug resistance
77. Different response to adriamycin vs. cytoxan-based chemotherapy in erbB-2 positive breast cancer is associated with alteration in topoisomerase II-alpha expression
78. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
79. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
80. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
81. Therapeutic advantage of chemotherapy drugs in combination with herceptin against human breast cancer cells with HER-2/neu overexpression
82. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
83. Combination adjuvant chemotherapy for node-positive breast cancer: Inadequacy of a single perioperative cycle
84. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer
85. Prognostic importance of c-erbB-2 expression in breast cancer
86. Adjuvant chemotherapy, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: An update of the Guy's/Manchester trial
87. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil
88. Combination chemotherapy as an adjuvant treatment in operable breast cancer
89. Benefit of CMF treatment in lymph node-positive breast cancer overexpressing HER-2
90. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
91. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer
92. Plasma c-erbB-2 levels in breast cancer patients: Prognostic significance in predicting response to chemotherapy
93. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer
94. Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients
95. Prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients with morphometry, DNA flow cytometry and HER-2/neu oncoprotein expression: Preliminary results
96. c-erbB-2 expression and S-phase activity predict response to adjuvant therapy in women with node-positive early breast cancer
97. erbB2, p53, and adjuvant therapy interactions in node positive breast cancer
98. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer
99. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
100. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone
101. Tamoxifen vs. cyclophosphamide, adriamycin, and 5FU plus either concurrent or sequential T in postmenopausal receptor positive, node positive breast cancer
102. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
103. HER2 overexpression as a predictor of survival in a trial comparing adjuvant FAC and CMF in breast cancer
104. CMF or anthracycline-based adjuvant chemotherapy for node-positive breast cancer patients: 4 year results of a Belgian randomized clinical trial with predictive markers analysis
105. HER2 and choice of adjuvant chemotherapy for invasive breast cancer
106. c-erbB-2 expression as a predictor of outcome in a randomized trial comparing adjuvant CMF vs. single agent epirubicin in stage I-II breast cancer patients
107. c-erbB-2 overexpression and treatment outcome in a randomized trial comparing adjuvant CMF and AC in equitoxic regimen in breast cancer
108. Impact of the overexpression of HER-2-neu gene and mutant P53 suppressive gene on response and disease free survival in patients with locally advanced breast cancer
109. c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy
110. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
111. Influence of TP53 gene alterations and HER-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
112. Prediction of response to neoadjuvant EC chemotherapy
113. Predictive value of c-erbB-2, p53, cathepsin-D, and histology of the primary tumour in metastatic breast cancer
114. Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients
115. The role of ERBB2 extracellular domain in predicting response to chemotherapy in breast cancer patients
116. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer
117. Response to mitoxantrone in advanced breast cancer: Correlation with expression of c-erbB-2 protein and glutathione S-transferases
118. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients
119. CMF vs. CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of intergroup trial INT0102
120. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
121. HER-2/neu overexpression and clinical taxane sensitivity: A multivariate analysis in patients with metastatic breast cancer
122. HER2 status predicts response to preoperative paclitaxel in patients with breast cancer
123. Pathological response to paclitaxel/radiation in locally advanced breast cancer: Association with molecular markers
124. Predictive value of c-erbB-2 expression for response to docetaxel or methotrexate-fluorouracil in advanced breast cancer
125. Correlation of circulating c-erbB-2 extracellular domain (HER-2) with clinical outcome in patients with metastatic breast cancer
126. Circulating HER-2/neu predicts resistance to Taxol/Adriamycin in metastatic breast carcinoma: Preliminary results of a multicentric study
127. Biweekly paclitaxel and gemcitabine in advanced breast cancer. Phase II trial and predictive value of HER2 extracellular domain
128. HER-2/neu amplification and response to doxorubicin/paclitaxel (AT) in women with metastatic breast cancer
129. Antibody dependent cellular phagocytosis (ADCP) of breast cancer cells mediated by bispecific antibody, MDX-210
130. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody herceptin in HER2-overexpressing metastatic breast cancer
131. Herceptin and vinorelbine as second-line therapy for HER-2-positive metastatic breast cancer: A phase II study
132. A phase II trial of docetaxel and herceptin in metastatic breast cancer patients overexpressing HER-2
133. Weekly docetaxel and rhumabher2 combination therapy as first- or second-line treatment for metastatic breast cancer
134. Weekly herceptin and one hour taxol infusion regimen for human epidermal growth factor receptor-2 overexpressed metastatic breast cancer
135. Baseline serum HER2 levels in the pivotal herceptin breast cancer trials: A comparison of 2 ELISA methods
136. Oncogene-transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype
137. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
138. Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study